Chandan sells pharmacy stake for Rs 16.77 crore to fund diagnostics
Key highlights
- Chandan sold a 53.56% stake in Chandan Pharmacy Limited for Rs 16.77 crore.
- The pharmacy sale generated a Rs 10.23 crore net-of-tax exceptional gain in Q2 FY27.
- Standalone H1 FY27 revenue rose 41.16% to Rs 106.61 crore and EBITDA margin reached 36.95%.
- Chandan had 685 franchise centres on 30 September 2026, with a stated FY27-end target of 1,000.
powered by IRIS

Chandan Healthcare Limited sold its 53.56% stake in Chandan Pharmacy Limited for Rs 16.77 crore in a transaction approved on 6 August 2026, completing the sale in Q2 FY27 and directing capital and management attention to diagnostics, where H1 FY27 standalone EBITDA margin was 36.95%.
Know Chandan Healthcare inside out
Results, valuation, peers and who's buying, in one view.
What exactly did Chandan sell in August 2026?
Chandan sold 1,72,992 equity shares, representing a 53.56% stake in Chandan Pharmacy Limited, to Chandan Hospital Limited, a group company, for Rs 16.77 crore. The board approved the transaction on 6 August 2026, and management said the sale of its entire pharmacy stake was completed during Q2 FY27, the quarter ended 30 September 2026.
The consideration was determined through an independent valuation report by a Registered Valuer, according to the presentation. Chandan describes the deal as an arm’s-length transaction, while the pharmacy business continues within the wider group through Chandan Hospital Limited rather than the listed diagnostics company.
The sale also produced a one-time exceptional gain in the standalone Q2 FY27 accounts. Chandan reported a Rs 10.23 crore net-of-tax gain, or Rs 12.03 crore before tax, from selling its investment in the pharmacy shares; management cautioned that quarterly profit growth should be read with this non-recurring item in mind.
Why did Chandan exit the pharmacy business?
Chandan exited pharmacy because more than 70% of that business’s revenue came from low-margin business-to-business, or B2B, supplies to a group company. Management said the disposal allows it to put both capital and management time behind diagnostics, which it described as a materially higher-margin activity.
The presentation frames the move as a portfolio simplification rather than an exit from the group’s healthcare ecosystem. Pharmacy continues under the group umbrella after the 6 August 2026 approval, but Chandan’s listed operations are intended to become more clearly diagnostics-led, spanning laboratory testing, diagnostic centres and collection-point franchises.
Chandan also said the transaction should provide a cleaner read of diagnostics performance. Its presentation states that the pharmacy subsidiary will be deconsolidated from H1 FY27, and that the most comparable base for evaluating subsequent performance is the previous year’s standalone financials of Chandan, rather than prior consolidated figures that included pharmacy.
How does the sale change Chandan’s reported financial comparison?
The sale changes the comparison basis because Chandan’s consolidated results will no longer include the pharmacy unit following the 53.56% stake disposal, while the presentation says standalone diagnostics economics are unaffected by deconsolidation. Chandan therefore directs readers to compare H1 FY27 standalone results with H1 FY26 standalone results when assessing diagnostics growth and margins.
Earnings before interest, tax, depreciation and amortisation, or EBITDA, increased faster than revenue in H1 FY27, lifting the standalone EBITDA margin by 576 basis points from 31.18% to 36.95%. Profit after tax, or PAT, included the Rs 10.23 crore net exceptional gain on the pharmacy sale, so the 256.72% PAT increase cannot be treated as entirely recurring diagnostics growth.
The same distinction applies to the Q2 FY27 comparison. Revenue increased 45.04% year on year to Rs 57.94 crore, and EBITDA rose 54.79% to Rs 22.12 crore, with EBITDA margin increasing from 34.85% to 37.26%. PAT reached Rs 18.61 crore from Rs 5.74 crore, but the reported Rs 10.23 crore exceptional gain accounted for a substantial part of that change.
Got a follow-up? Ask IRIS
Where will Chandan deploy the pharmacy-sale proceeds?
Chandan says the Rs 16.77 crore proceeds will fund new diagnostic centres and capacity additions. Management also said it would allocate capital toward new diagnostic centres where returns are higher, alongside efforts to improve utilisation across its network during the remainder of FY27.
The franchise network is one route for extending diagnostics without company-funded local infrastructure. Chandan had 685 franchise centres as of 30 September 2026, compared with 264 at 30 June 2026, after adding 421 centres during Q2 FY27. Under this model, franchise partners bear local infrastructure and operating costs, while Chandan supplies diagnostic capability, quality protocols, branding and support.
Management’s stated FY27-end target is 1,000 franchise centres, followed by a target of 3,000 over the next two years. About 80% of the network was in Uttar Pradesh as of the presentation, and management said the next phase would extend the model into newer geographies, using laboratories and diagnostic centres as hubs for samples collected through franchise points.
Chandan also added two acquired units of Ansh Diagnostics & Health Care in Ghaziabad, Uttar Pradesh, under an agreement dated 25 September 2026. The units provide pathology and radiology services, including computed tomography, or CT, and magnetic resonance imaging, or MRI, giving Chandan operating diagnostic capacity in the Delhi National Capital Region alongside its organic franchise and owned-centre expansion.
Conclusion
The pharmacy disposal separates Chandan from a business where more than 70% of revenue was low-margin B2B supply, while realising Rs 16.77 crore through an independently valued sale to a group company. The resulting structure puts diagnostics at the centre of reported operations, although the one-time Rs 10.23 crore net gain means H1 FY27 PAT growth needs to be distinguished from operating performance.
The next disclosed milestones are management’s plan to reach 1,000 franchise centres by FY27-end, add owned diagnostic centres in selected markets, and deploy capital into diagnostic capacity. Readers can watch whether the network grows from 685 centres as at 30 September 2026 and whether revenue, EBITDA and utilisation continue to improve on the standalone diagnostics comparison base.


